How Liraglutide Controls Fat Metabolism Through the ZBTB20-LPL Pathway | Research

The takeaway

Liraglutide reduces fat accumulation by downregulating the transcriptional suppressor ZBTB20, which releases a key fat-breakdown enzyme (LPL), revealing a specific molecular mechanism for how this GLP-1 drug affects lipid metabolism.

ZBTB20-LPL pathway identified
Liraglutide reduces fat accumulation by downregulating ZBTB20, releasing the brake on lipoprotein lipase — a key fat-breakdown enzyme

What the researchers found

Liraglutide regulates lipid metabolism through a newly identified ZBTB20-LPL pathway:

**In vitro (3T3-L1 adipocytes):**

- Reduced lipid droplets and triglyceride (TG) levels

- Altered expression of genes involved in fatty acid metabolism, lipogenesis, fatty acid oxidation, and adipocyte browning

- Downregulated ZBTB20, a transcriptional suppressor

- ZBTB20 overexpression confirmed it inhibits LPL (lipoprotein lipase) expression

**In vivo (ob/ob obese mice, 4 weeks):**

- Improved blood lipid levels

- Reduced adipose tissue volume and adipocyte size

- Confirmed ZBTB20-LPL pathway regulation in adipose tissue

This establishes a molecular mechanism: liraglutide → reduced ZBTB20 → increased LPL → enhanced lipid breakdown.

Why it matters

While liraglutide is widely prescribed for diabetes and weight loss, understanding its specific molecular mechanisms for fat reduction helps explain why it works and could guide the development of more targeted therapies. The ZBTB20-LPL pathway is a novel finding that adds to our understanding of GLP-1 drug biology and could identify new drug targets for lipid disorders.

How the study worked

In vitro: 3T3-L1 preadipocytes were differentiated into adipocytes and treated with liraglutide. RNA sequencing identified differentially expressed genes, with GO and KEGG enrichment analyses pinpointing lipid regulation targets. Lentiviral overexpression of Zbtb20 validated its role. In vivo: ob/ob mice received subcutaneous liraglutide or saline for 4 weeks. Outcomes included blood lipids, adipose tissue volume, adipocyte size, and target gene expression via immunohistochemistry and RT-qPCR.

What this study cannot tell us

The study used an established cell line (3T3-L1) and a genetic obesity mouse model (ob/ob), which may not perfectly represent human adipose tissue biology. The 4-week in vivo treatment period is relatively short. The study focused on one pathway (ZBTB20-LPL), but liraglutide likely affects lipid metabolism through multiple mechanisms simultaneously. Whether the ZBTB20-LPL pathway is the primary driver of liraglutide's lipid effects in humans remains to be determined.

How to read the evidence

This is a preclinical mechanistic study using cell culture and an obese mouse model. The multi-method approach (RNA-seq, overexpression studies, in vivo validation) provides solid mechanistic evidence. However, the findings are from animal models and need human validation.

When this study was published

Published in 2025, this study adds to the growing molecular understanding of how GLP-1 drugs affect fat metabolism. The ZBTB20-LPL pathway is a novel finding that may inform future research and drug development.

The bigger picture

GLP-1 receptor agonists clearly improve lipid profiles in patients, but the mechanisms have been incompletely understood. This study adds a specific molecular pathway to the picture: liraglutide acts through ZBTB20 to unlock LPL-mediated fat breakdown. As the field moves toward precision medicine, understanding these specific pathways could help predict which patients will respond best to GLP-1 therapy and could inspire new drugs targeting the ZBTB20-LPL axis directly.

Questions still open

Is the ZBTB20-LPL pathway active in human adipose tissue, and does it explain the lipid improvements seen in clinical trials of liraglutide?
Could directly targeting ZBTB20 produce lipid-lowering effects without the GI side effects of GLP-1 receptor agonists?
Do other GLP-1 drugs (semaglutide, tirzepatide) also modulate the ZBTB20-LPL pathway?

Common questions

What is the ZBTB20-LPL pathway?

ZBTB20 is a protein that normally acts as a 'brake' on fat breakdown by suppressing the production of LPL (lipoprotein lipase), a key enzyme that breaks down fats in the blood. Liraglutide releases this brake by reducing ZBTB20 levels, allowing more LPL to be produced and more fat to be broken down. Think of it as removing a roadblock that was preventing fat metabolism.

Does this explain why GLP-1 drugs improve cholesterol?

It's part of the explanation. Patients taking GLP-1 drugs typically see improvements in blood triglycerides and cholesterol. This study shows one mechanism: by increasing LPL activity through the ZBTB20 pathway, liraglutide enhances the clearance of triglyceride-rich particles from the blood. However, GLP-1 drugs likely improve lipids through multiple mechanisms, including weight loss and direct effects on the liver.

Read the original research

Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway.

Life sciences, 360, 123267

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Yue; Gao, Rui; Yang, Zhiyan; Zong, Huiying; Li, Yan. (2025). Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway.. Life sciences, 360, 123267. https://doi.org/10.1016/j.lfs.2024.123267